Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Antengene Approved to Start China Trial of Endometrial Cancer Therapy

publication date: May 13, 2021

Antengene of Shanghai announced China approved a Phase III trial of selinexor (XPOVIO®) to treat advanced or recurrent endometrial cancer. Selinexor is an only-in-class oral selective inhibitor of nuclear export (SINE) that was discovered and developed by Karyopharm of Boston. In 2018, Antengene in-licensed greater China rights to Selinexor as part of a $162 million, four-drug deal. Selinexor is approved in the US to treat multiple myeloma and diffuse large B-cell lymphoma. More details...

Stock Symbol: (HK: 6996) (NSDQ: KPTI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.